It has been our deep honor and pleasure at Nanobiosym to partner with the FDA in transforming the Digital Diagnostics Landscape
The FDA's Diagnostic Data Program has achieved significant milestones in the past year, including: · Worked across the interagency and with external stakeholders to improve the quality and utility of diagnostic data, as well as its flow between individuals and institutions who need it. · Provided enhanced regulatory support and guidance to ensure that new and advanced diagnostic technologies will be safe, effective, and timely in their introduction to the U.S. market. · Supported projects with collaborating institutions and investigators including allocating approximately $100M to extramural teams for projects that advance the FDA’s mission and goals. · Driven improvements in data quality from over-the-counter, point-of-care, and lab-based diagnostic tests that help inform patient care, population health, and regulatory decision-making. · Developed a regulatory data sandbox to facilitate the development of analytical tools to support regulatory review, starting with specific use cases that integrate both new (e.g., real-world data) and traditional sources of data. Check out our latest update and learn more about opportunities for engagement, including applying for future funding. https://lnkd.in/echbbAVY